• Pear Therapeutics merges with Thimble Point Acquisition Corp, forming Pear Holdings Corp (ticker PEAR). • Deal values Pear at ~$1.6B, marking a significant SPAC exit in digital health. • SPACs increasingly target high‑growth tech, widening supply‑demand mismatch for digital health companies. • Pear pioneered “prescription digital therapeutics,” first FDA‑cleared PDT with reSET®. • Public listing injects capital, enabling Pear to build infrastructure for end‑to‑end PDT platform. • The move highlights growing investor interest in technology‑enabled healthcare disruption.

Article Summaries:

  • Pear Therapeutics will go public through a $1.6 billion SPAC merger with Thimble Point Acquisition Corp., forming Pear Holdings Corp. (ticker PEAR). The deal highlights a growing supply‑demand gap in the digital‑health SPAC market, as non‑health‑focused sponsors increasingly target capital‑rich tech firms. Pear, a pioneer of prescription digital therapeutics (PDTs) and the first FDA‑cleared PDT, will receive fresh capital to expand its end‑to‑end platform. Management sees two paths: use funds for acquisitions to broaden therapeutic reach or enhance its PDT development infrastructure with newly licensed technologies. The public listing positions Pear to accelerate growth and potentially become a broader digital‑health platform provider.

Sources: